醋酸茚达特罗/格隆溴铵/莫米松糠酸酯(Indacaterol Acetate/Glycopyrronium Bromide/ Mometasone Furoate) - 药物靶点：GR x mAChRs x β2-adrenergic receptor_在研适应症：哮喘_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Glycopyrrolate/indacaterol/mometasone、IND/GLY/MF、QVM 149

+ [7]

靶点

GR x mAChRs x β2-adrenergic receptor

作用机制

GR激动剂(糖皮质激素受体激动剂)、mAChRs拮抗剂(毒蕈碱型乙酰胆碱受体家族拮抗剂)、β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Novartis Pharmaceuticals Corp.Novartis Europharm Ltd.Novartis Pharma AG

+ [2]

非在研机构

北京诺华制药有限公司Novartis Pharma Stein AG

Novartis AG

最高研发阶段批准上市

首次获批日期

日本 (2020-06-29),

哮喘

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C28H32N2O7

InChIKeyIREJFXIHXRZFER-PCBAQXHCSA-N

CAS号753498-25-8

查看全部结构式(3)

关联

21

项与醋酸茚达特罗/格隆溴铵/莫米松糠酸酯相关的临床试验

NCT05776927

/ Not yet recruiting临床3期

A Double-dummy, Double-blind, Randomized, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Compared to Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

A double-dummy, double-blind, randomized, parallel-group, active controlled study to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.

开始日期2026-02-01

申办/合作机构

Novartis Pharmaceuticals Corp.

CTR20242209

/ CompletedN/A

茚达格莫吸入粉雾剂（Ⅱ）在中国健康受试者中随机、开放、两制剂、单次给药空腹状态下的生物等效性试验

以北京抗创联生物制药技术研究有限公司研发的茚达格莫吸入粉雾剂（Ⅱ）（规格：150 μg /50 μg/160 μg）为受试制剂，按生物等效性试验的有关规定，以Novartis Pharma AG 持证的茚达格莫吸入粉雾剂（Ⅱ）（规格：150 μg /50 μg/160 μg；商品名：Enerzair®）为参比制剂，对比在健康人体内的吸收速度及吸收程度，考察两制剂的人体生物等效性。次要目的：观察受试制剂茚达格莫吸入粉雾剂（Ⅱ）和参比制剂茚达格莫吸入粉雾剂（Ⅱ）（Enerzair®）在健康受试者中的安全性。

开始日期2024-07-09

申办/合作机构

北京抗创联生物制药技术研究有限公司

NCT05562466

/ Recruiting临床3期

Double-blind, Randomized, Active-controlled, Two-way Cross-over Study, With 12-week Treatment Duration Per Period, to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate / Mometasone Furoate) Compared to Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

The purpose of this study is to evaluate the superiority in terms of efficacy and evaluate the safety of QMF149 (indacaterol (acetate) / mometasone (furoate)) compared to budesonide in children from 6 to less than 12 years of age with asthma.
* The study duration will be up to 37 weeks including an investigational treatment duration of 12 weeks and a comparator treatment duration of 12 weeks.
* The visit frequency will be 3 weeks for screening, run-in and wash-out period, 6 weeks interval for visits during each treatment period, 30 days for safety follow-up.

开始日期2023-05-11

申办/合作机构

Novartis Pharmaceuticals Corp.

100 项与醋酸茚达特罗/格隆溴铵/莫米松糠酸酯相关的临床结果

登录后查看更多信息

100 项与醋酸茚达特罗/格隆溴铵/莫米松糠酸酯相关的转化医学

登录后查看更多信息

100 项与醋酸茚达特罗/格隆溴铵/莫米松糠酸酯相关的专利（医药）

登录后查看更多信息

44

项与醋酸茚达特罗/格隆溴铵/莫米松糠酸酯相关的文献（医药）

2024-07-01·Respiratory Investigation

Real-world characteristics of patients with asthma initiating fluticasone furoate/umeclidinium/vilanterol single-inhaler triple therapy in Japan

Article

作者: Yarita, Masao ; Yuanita, Liza ; Oga, Toru ; Ito, Risako ; Requena, Gema ; Noorduyn, Stephen G ; Mita, Chifuku ; Rothnie, Kieran J

BACKGROUND:

Real-world data assessing characteristics of patients with asthma initiating inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β₂-agonist (ICS/LAMA/LABA) triple therapy in Japan are limited.

METHODS:

Descriptive, observational study of patients with asthma aged ≥15 years newly initiating single- or multiple-inhaler triple therapy (SITT: fluticasone furoate/umeclidinium/vilanterol [FF/UMEC/VI], SITT: indacaterol/glycopyrronium bromide/mometasone furoate [IND/GLY/MF] or MITT) or ICS/LABA using JMDC/Medical Data Vision (MDV) health insurance databases from February 2021-February 2022 (first prescription date: index date). Patients were assigned to three non-mutually exclusive cohorts: A) new FF/UMEC/VI initiators; B) new FF/UMEC/VI, IND/GLY/MF, or MITT initiators; C) new FF/UMEC/VI, IND/GLY/MF, MITT or ICS/LABA initiators as initial maintenance therapy (IMT). Patient characteristics were assessed descriptively for 12-months pre-treatment initiation (baseline period).

RESULTS:

Cohort A: among new FF/UMEC/VI initiators, 12.8% and 0.1% (JMDC) and 21.7% and 0.9% (MDV) of patients had ≥1 moderate and severe exacerbation; 52.0% (JMDC) and 79.2% (MDV) had ICS/LABA use. Cohort B: most patients initiated FF/UMEC/VI and IND/GLY/MF over MITT (JMDC: 91.3% vs 8.7%; MDV: 67.8% vs 32.2%), with fewer exacerbations and lower rescue medication use. Cohort C: a greater proportion of FF/UMEC/VI initiators as IMT experienced a moderate exacerbation at index versus ICS/LABA initiators as IMT (JMDC: 17.8% vs 10.7%; MDV: 8.0% vs 5.1%).

CONCLUSIONS:

Patient characteristics were generally similar between treatment groups; SITT initiators had fewer exacerbations and lower rescue medication use than MITT initiators, represented by the greater proportion of IMT among SITT versus MITT initiators. Physicians may have prescribed triple over dual therapy as IMT in response to an exacerbation.

2023-10-01·Respiratory medicine

Efficacy of mometasone/indacaterol/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM study.

Article

作者: Maspero, Jorge F ; Mezzi, Karen ; Chapman, Kenneth R ; Lawrence, David ; Kostikas, Konstantinos ; van Zyl-Smit, Richard ; Jaumont, Xavier

BACKGROUND:

Baseline characteristics could potentially guide asthma treatments. We evaluated whether baseline eosinophil levels affect the efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) in patients with inadequately controlled asthma.

METHOD:

In this post hoc analysis of IRIDIUM study, efficacy of high-dose MF/IND/GLY (160/150/50 μg, once-daily [o.d.]) versus high-dose MF/IND (320/150 μg o.d.) and high-dose fluticasone/salmeterol (FLU/SAL [500/50 μg, twice-daily [b.i.d.]); and efficacy of pooled MF/IND/GLY (160/150/50 μg and 80/150/50 μg) versus pooled MF/IND (320/150 μg and 160/150 μg) was evaluated in patient subgroups with baseline blood eosinophil count of <300 cells/μL or ≥300 cells/μL.

RESULTS:

Overall, 3065 patients were included. At Week 26, high-dose MF/IND/GLY showed improved trough FEV₁ versus high-dose MF/IND (Δ78mL [<300 cells/μL]; Δ54mL [≥300 cells/μL]) and FLU/SAL (Δ112mL [<300 cells/μL]; Δ98mL [≥300 cells/μL]). Similarly, pooled MF/IND/GLY also showed improved trough FEV₁ versus pooled MF/IND (Δ75mL [<300 cells/μL]; Δ68mL [≥300 cells/μL]). Over 52 weeks, high-dose MF/IND/GLY reduced the annualized rate of moderate or severe asthma exacerbations by 23% and 10%, severe exacerbations by 31% and 15%, and all exacerbation by 33% and 10% versus high-dose MF/IND for subgroups with <300 cells/μL and ≥300 cells/μL, respectively; and by 33% and 41%, 45% and 42%, 42% and 39% versus FLU/SAL, respectively. Similarly, pooled MF/IND/GLY reduced exacerbations by 22% and 8%, 21% and 7%, 27% and 8%, versus pooled MF/IND, for the respective subgroups.

CONCLUSION:

MF/IND/GLY showed improvement in lung function and reduction in asthma exacerbations over MF/IND and FLU/SAL independent of baseline eosinophil levels, indicating that eosinophil levels did not affect the efficacy of MF/IND/GLY in patients with inadequately controlled asthma.

TRIAL REGISTRATION:

ClinicalTrials.gov, NCT02571777 (IRIDIUM).

2023-04-01·Chest

Comparison of Clinical Outcomes Among Different Fixed-Dose Combinations of Long-Acting Muscarinic Antagonists and Long-Acting β2-Agonists in Patients With COPD

Article

作者: Wu, Chien-Chih ; Wu, Mei-Hsuan ; Weng, Ching-Fu ; Lin, Fang-Ju

BACKGROUND:

Researchers have yet to obtain conclusive evidence differentiating among fixed-dose combinations (FDCs) of long-acting muscarinic antagonists (LAMAs) and long-acting β₂-agonists (LABAs) for COPD in terms of real-world clinical outcomes.

RESEARCH QUESTION:

What are the differences between available LAMA/LABA FDCs in the risk of acute exacerbation (AE) and cardiovascular events?

STUDY DESIGN AND METHODS:

This retrospective cohort study based on a national insurance claims database included patients with COPD ≥ 40 years of age who were newly prescribed glycopyrronium (GLY)/indacaterol (IND), umeclidinium (UMEC)/vilanterol (VI), or tiotropium (TIO)/olodaterol (OLO) FDC between January 1, 2015, and June 30, 2019. Propensity score matching and Cox regression models were used to compare outcomes of AE and cardiovascular events associated with LAMA/LABA FDC treatment.

RESULTS:

Among the 44,498 patients identified and included, 15,586 received GLY/IND, 20,460 received UMEC/VI, and 8,452 received TIO/OLO. Baseline characteristics were well balanced after 1:1 matching of UMEC/VI and GLY/IND, 2:1 matching of UMEC/VI and TIO/OLO, and 2:1 matching of GLY/IND and TIO/OLO. Risk of severe AE was lower among patients treated with UMEC/VI or GLY/IND than among those who received TIO/OLO (UMEC/VI vs TIO/OLO: 17.85 vs 29.32 per 100 person-years; hazard ratio, 0.76; 95% CI, 0.68-0.84; GLY/IND vs TIO/OLO: 15.54 vs 25.53 per 100 person-years; hazard ratio, 0.77; 95% CI, 0.67-0.88). In addition, GLY/IND users tended to have a lower risk of cardiovascular events than TIO/OLO users, but the difference dissipated when restricting follow up to a shorter duration.

INTERPRETATION:

Our results revealed that the risk of severe AE was lower among patients with COPD receiving UMEC/VI or GLY/IND than among those receiving TIO/OLO, whereas the incidence of cardiovascular events was similar across groups but was slightly lower in GLY/IND users when compared with TIO/OLO users. Further research will be required to confirm these findings.

2

项与醋酸茚达特罗/格隆溴铵/莫米松糠酸酯相关的新闻（医药）

2021-09-03

·BioSpace

Novartis Scuttles Kidney Transplant Drug Study

Harold Cunningham/Getty Images Novartis announced that after conducting an interim analysis from its CIRRUS-1 trial of CFZ533 (iscalimab), it is discontinuing the trial in kidney transplant patients. The drug is dosed with tacrolimus and other immunosuppressive therapies to prevent organ rejection. The company indicated the drug would continue to be developed to treat hidradenitis suppurativa and Sjögen’s syndrome and other autoimmune diseases. It is currently being evaluated in the Phase II CONTRAIL trial in liver transplant patients and other studies in type 1 diabetes and lupus nephritis. The study data apparently indicated that iscalimab was not as effective as tacrolimus at preventing organ rejection in kidney transplant patients when both were added to standard immunosuppressive therapies. Those therapies included drugs such as mycophenolate mofetil and corticosteroids. Earlier studies suggested iscalimab might be more effective than tacrolimus. In those studies, patients had kidney biopsies as healthy as normal kidneys about one year after transplant. Studies show that less than 50% of donated kidneys last 10 years. Any therapy that can extend the life of donated kidneys would have a significant impact on patients and donor organ availability. Worldwide, there are approximately 3.2 million people with end-stage renal disease. The CIRRUS-1 trial evaluated 418 transplant patients and studied three different doses of iscalimab. The drug is a fully human antibody that targets the CD40 antigen. It is engineered to inhibit immune reactions to foreign transplanted tissue. The study was expected to run to at least 2023. Novartis also announced that it is presenting abstracts at the upcoming European Respiratory Society (ERS) International Congress 2021 from September 5 to 8 on its 12 Enerzair Breezhaler and Atectura Breezhaler. The data continues to support the efficacy of Enerzair Breezher, and there will also be an interim analysis of patient engagement and adherence levels of the Enerzair Breezhaler’s optional digital companion. “Our presence at ERS this year reiterates our commitment to patients through the further development of first-in-class therapies like Enerzair Breezhaler, as well as by exploring the potential of digital health companions and the carbon footprint of our solutions,” said Dominic Brittain, Respiratory Global Program Head, Novartis Pharmaceuticals. “As a global leader in respiratory and allergy, we remain committed to reimagining medicine for patients living with chronic respiratory diseases like asthma.” And on September 1, Novartis inked a commercial agreement with the National Health Service (NHS) in England as part of a collaboration to develop a population health management approach for high cholesterol levels in patients with atherosclerotic cardiovascular disease (ASCVD). This deal comes after a positive final recommendation from the National Institute for Health and Care Excellence (NICE) for using inclisiran in primary care for adults for its licensed indication. It is licensed in Europe for adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, in addition to diet modification. “High cholesterol is a major cause of cardiovascular disease—disease of the heart and blood vessels,” said Jules Payne, chief executive at HEART UK, the cholesterol charity. “It is very common and can affect anyone including those who are young, slim, fit and active. HEART UK looks forward to continuing our leading role in helping people effectively manage their cholesterol and we warmly welcome the collaboration between Novartis and the NHS to enable more people to access this innovative medicine.”

合作抗体First in Class

2021-04-27

·BioSpace

Valeo Pharma Upsizes And Closes $6.6 Million Non-Brokered Private Placement

Valeo insiders participation of $2.6 million MONTRÉAL, April 27, 2021 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has upsized and closed a $6.645 million non-brokered private placement of unsecured non-convertible debenture units (the "Private Placement"). The Company issued 6,645 unsecured non-convertible debentures units (the "Debenture Units") at a purchase price of $1,000 per Debenture Unit for gross proceeds of $6,645,000. Each Debenture Unit consist of one (1) unsecured non-convertible debenture of the Company in the principal amount of $1,000 (each, a "Debenture") and 200 Class "A" share purchase warrants (each, a "Warrant"). Each Warrant entitles the holder thereof to purchase one Class "A" Share of the Company (each, a "Share") at an exercise price of $1.60 at any time up to 24 months following the closing date of the Offering (the "Closing Date"). The Debentures will mature at the latest 9 months after the closing and bear interest at a rate of 8% per annum from the date of issue, payable in cash, semi-annually in arrears. "The closing of this upsized placement is testament to the confidence and support our insiders and those close to the Company have in management and Valeo's business model", said Steve Saviuk, CEO. "I cannot over emphasize what a pivotal year 2021 is becoming with the recent launch of Redesca® and the imminent launches of Enerzair® Breezhaler® and Atectura® Breezhaler®". The securities issued under the Private Placement are subject to a four-month hold period in accordance with applicable securities legislation. The Company has paid $38,500 as finder's fees to arm's-length parties in connection with the Private Placement and issued a total of 7,700 broker warrants in compliance with applicable securities laws. Insiders, Senior Executives, staff members and 3 Directors of the Company all participated in the Private Placement for an aggregate amount of $2.6 million. The net proceeds of the Offering will be used for working capital and general corporate purposes. Participation of insiders of the Company in the Private Placement constitutes a "related party transaction" as defined under Regulation 61-101 respecting Protection of Minority Security Holders in Special Transactions ("Regulation 61-101"). The Company intends to rely on exemptions from the formal valuation and minority shareholder approval requirements provided under sections 5.5(a) and 5.7(a) of Regulation 61-101 on the basis that participation in the Private Placement by insiders will not exceed 25% of the fair market value of the Company's market capitalization and also because the Company's Common Shares trade only on the Canadian Securities Exchange (CSE). A material change report was not filed in connection with the participation of the insiders in at least 21 days in advance of the closing of the Private Placement, which the Company deemed reasonable in the circumstances, in order to close the transaction as soon as practicable to enable it to use the funds. About Valeo Pharma Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurology, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit and follow us on LinkedIn and Twitter. Forward Looking Statements This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Company Codes: OTC-QB:VPHIF, CNSX:VPH, Frankfurt:VP2, OTC-PINK:VPHIF

100 项与醋酸茚达特罗/格隆溴铵/莫米松糠酸酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	R03AL	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
哮喘	日本	Novartis Pharma AG	2020-06-29

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
过敏性哮喘	临床3期	荷兰	Novartis AG	2020-09-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04589663 (CTgov)	临床2期	哮喘	24	Standard of Care (Soc)+Mometasone furoate+QMF149	願艱餘衊網簾簾遞憲選(鹹繭觸顧醖鹹憲醖窪鬱) = 網鑰獵鏇夢夢積簾願範衊廠鏇醖遞鹹窪衊齋糧 (蓋齋淵網窪醖選製構齋, 淵鑰構鹹醖壓醖鹽鹹鬱 ~ 願窪顧鏇艱淵觸網鹽簾) 更多	-	2023-07-27
Pubmed 人工标引	临床3期	哮喘	145	indacaterol acetate+glycopyrronium bromide+mometasone furoate	築醖簾夢鑰鹽膚衊築觸(憲艱簾鹽蓋顧糧鹹醖窪) = 願鑰網鑰夢襯鹽願齋壓膚襯觸積鹹鹽淵鹹願鑰 (構製鏇遞夢構築鹹壓構 ) 更多	积极	2022-05-30
				indacaterol acetate+mometasone furoate	築醖簾夢鑰鹽膚衊築觸(憲艱簾鹽蓋顧糧鹹醖窪) = 範選醖構簾齋範遞蓋網膚襯觸積鹹鹽淵鹹願鑰 (構製鏇遞夢構築鹹壓構 ) 更多
ERS2021	N/A	哮喘	135	indacaterol/glycopyrronium/mometasone (IND/GLY/MF) Breezhaler	膚醖範衊鑰願窪餘壓壓(觸積鑰願艱窪選簾鹹積) = 壓窪觸網齋遞憲製獵襯廠膚積鏇夢繭醖簾獵獵 (壓蓋醖鑰餘繭鹽鹽衊範 )	-	2021-09-05
AAAAI2021	临床1期	-	24	IND/GLY/MF medium-dose	繭構簾餘餘觸廠簾糧糧(網壓餘夢夢願醖壓繭夢) = 鑰顧鹹衊壓鹹糧積築襯築構鏇簾選襯淵築壓壓 (製積顧願顧夢窪網齋襯 ) 更多	-	2021-02-01
				IND/GLY/MF high-dose	繭構簾餘餘觸廠簾糧糧(網壓餘夢夢願醖壓繭夢) = 艱製淵鏇壓網壓顧製壓築構鏇簾選襯淵築壓壓 (製積顧願顧夢窪網齋襯 ) 更多
NCT03158311 (ARGON, CTgov)	临床3期	哮喘	1,426	QVM149 (QVM149 150/50/80 μg)	構衊遞製繭鑰膚襯窪鹹(積餘繭願憲築醖簾夢艱) = 鏇鑰鹹鹹顧夢窪製醖鹽顧蓋壓遞願淵糧鑰糧簾 (遞夢範窪餘膚窪憲築獵, 艱廠遞願夢壓齋糧願淵 ~ 齋築餘簾憲壓築廠鬱願) 更多	-	2020-10-14
				QVM149 (QVM149 150/50/160 μg)	構衊遞製繭鑰膚襯窪鹹(積餘繭願憲築醖簾夢艱) = 窪廠膚膚構範淵鑰遞鹹顧蓋壓遞願淵糧鑰糧簾 (遞夢範窪餘膚窪憲築獵, 鹹壓廠艱蓋壓網簾鬱範 ~ 選糧簾艱構鹹簾齋鹹構) 更多
NCT02571777 (IRIDIUM, CTgov)	临床3期	哮喘	3,092	QVM149 150/50/160 (QVM149 150/50/160 µg o.d.)	顧艱繭壓憲鬱製築製鹹(網憲願壓餘構窪壓窪醖) = 醖糧顧壓壓構襯窪願艱糧窪繭願網網夢壓壓壓 (鹹鬱淵蓋築遞觸繭觸網, 餘簾餘餘簾鬱獵窪鏇簾 ~ 願繭醖鑰鑰製糧顧積壓) 更多	-	2020-07-22
				QVM149 150/50/80 (QVM149 150/50/80 µg o.d.)	顧艱繭壓憲鬱製築製鹹(網憲願壓餘構窪壓窪醖) = 壓鏇鑰繭構膚鬱夢願鹹糧窪繭願網網夢壓壓壓 (鹹鬱淵蓋築遞觸繭觸網, 淵淵齋範顧糧顧廠衊範 ~ 顧選顧鬱簾鹽觸網積繭) 更多
NCT03100825 (CTgov)	临床3期	哮喘	96	QVM149	選簾鏇鬱壓蓋憲淵夢願(蓋繭鬱淵築膚範築鹹願) = 鹽積觸蓋積觸獵獵廠鹽構夢製構夢製鑰鹽夢網 (製選網艱獵膚窪憲壓繭, 鏇網鏇鑰窪憲壓齋築醖 ~ 願餘夢艱積鏇鏇艱鹹衊) 更多	-	2020-04-07
ERS2019	N/A	-	10	salmeterol/fluticasone	膚憲餘夢廠餘醖膚築醖(鹹顧憲築餘廠顧選襯選) = 廠壓餘鏇鹹襯壓衊齋構鬱觸鹽齋願廠膚夢遞鬱 (蓋構鑰鹽齋遞願鑰窪夢 )	积极	2019-09-28
				salmeterol/fluticasone	膚憲餘夢廠餘醖膚築醖(鹹顧憲築餘廠顧選襯選) = 餘壓鏇鬱構築鏇獵製鏇鬱觸鹽齋願廠膚夢遞鬱 (蓋構鑰鹽齋遞願鑰窪夢 )
ERS2012	N/A	哮喘 exhaled nitic oxide (FeNO) \| serum C reactive protein (CRP)	13	Salmeterol/fluticasone (Seretide Discus) 50/250 mcg	繭淵繭積簾窪蓋糧憲繭(願築廠簾遞廠蓋艱顧淵) = 膚艱淵餘壓鹹築積憲淵鹹鏇齋衊繭觸遞製廠壓 (壓繭積繭鹹壓觸獵獵願 ) 更多	-	2012-09-01